NICE recommends Vitrakvi to treat neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors. Bayer HealthCare

Vitrakvi (larotrectinib) from Bayer HealthCare, has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of advanced neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors for patients who have no other satisfactory treatment options. The oral drug will become the first histology-independent treatment to be made available for NHS patients in England through the country’s Cancer Drugs Fund .

This positive recommendation is a change in position for NICE to the initial decision where the price of larotrectinib was too high to be considered cost-effective.